Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19. Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients. The company announced the study’s partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists. The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals. Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.
What does intravenous mean?
by mouth
through a vein
using your eyes
application to skin
What does Lilly hope to accomplish with the experimental treatment?
to cure those with COVID-19
to reduce emergency room visits for persons with mild or moderate forms of COVID-19
to prevent people from catching the novel coronavirus
to increase hospitalization for those with moderate forms of COVID-19
Drug maker Eli Lilly asked U.S. officials to approve emergency use of an experimental antibody treatment.
antibody treatment
eye test
vaccine
rehab procedure